Who are ARTICE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Oral PF-07220060.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/artice.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ARTICE — Competitive Intelligence Brief

ARTICE (ARTICE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule inhibitor. Area: Cardiovascular.

phase 2 Small molecule inhibitor Unknown Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

ARTICE (ARTICE) — Artcline GmbH. ARTICE is a small molecule that targets the underlying cause of a specific disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARTICE TARGET	ARTICE	Artcline GmbH	phase 2	Small molecule inhibitor	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Open-label, PK Cohort (Cohort B): ponsegromab low dose	open-label-pk-cohort-cohort-b-ponsegromab-low-dose	Pfizer	marketed	Unknown	Unknown
Oral PF-07220060	oral-pf-07220060	Pfizer	marketed	Unknown	Unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Small molecule inhibitor class)

Pfizer · 8 drugs in this class
Artcline GmbH · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Rennes University Hospital · 1 drug in this class
The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARTICE — Competitive Intelligence Brief. https://druglandscape.com/ci/artice. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab